Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.31
IDXX's Cash to Debt is ranked lower than
82% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. IDXX: 0.31 )
Ranked among companies with meaningful Cash to Debt only.
IDXX' s 10-Year Cash to Debt Range
Min: 0.31  Med: 9.79 Max: No Debt
Current: 0.31
Equity to Asset 0.01
IDXX's Equity to Asset is ranked lower than
92% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. IDXX: 0.01 )
Ranked among companies with meaningful Equity to Asset only.
IDXX' s 10-Year Equity to Asset Range
Min: 0.01  Med: 0.77 Max: 0.9
Current: 0.01
0.01
0.9
Interest Coverage 16.87
IDXX's Interest Coverage is ranked lower than
73% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1009.34 vs. IDXX: 16.87 )
Ranked among companies with meaningful Interest Coverage only.
IDXX' s 10-Year Interest Coverage Range
Min: 16.87  Med: 276.91 Max: 9999.99
Current: 16.87
16.87
9999.99
F-Score: 4
Z-Score: 4.64
M-Score: -2.56
WACC vs ROIC
2.23%
27.76%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 17.51
IDXX's Operating margin (%) is ranked higher than
89% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. IDXX: 17.51 )
Ranked among companies with meaningful Operating margin (%) only.
IDXX' s 10-Year Operating margin (%) Range
Min: -1.67  Med: 17.19 Max: 20.3
Current: 17.51
-1.67
20.3
Net-margin (%) 11.86
IDXX's Net-margin (%) is ranked higher than
86% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.26 vs. IDXX: 11.86 )
Ranked among companies with meaningful Net-margin (%) only.
IDXX' s 10-Year Net-margin (%) Range
Min: -8.02  Med: 11.92 Max: 14.26
Current: 11.86
-8.02
14.26
ROE (%) 107.81
IDXX's ROE (%) is ranked higher than
99% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.76 vs. IDXX: 107.81 )
Ranked among companies with meaningful ROE (%) only.
IDXX' s 10-Year ROE (%) Range
Min: -6.75  Med: 20.41 Max: 57.23
Current: 107.81
-6.75
57.23
ROA (%) 13.22
IDXX's ROA (%) is ranked higher than
94% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.65 vs. IDXX: 13.22 )
Ranked among companies with meaningful ROA (%) only.
IDXX' s 10-Year ROA (%) Range
Min: -5.62  Med: 14.90 Max: 17.84
Current: 13.22
-5.62
17.84
ROC (Joel Greenblatt) (%) 54.78
IDXX's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.66 vs. IDXX: 54.78 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IDXX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2.93  Med: 59.90 Max: 99.54
Current: 54.78
-2.93
99.54
Revenue Growth (3Y)(%) 11.80
IDXX's Revenue Growth (3Y)(%) is ranked higher than
75% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. IDXX: 11.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IDXX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 8.4  Med: 11.20 Max: 23.1
Current: 11.8
8.4
23.1
EBITDA Growth (3Y)(%) 8.70
IDXX's EBITDA Growth (3Y)(%) is ranked higher than
62% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. IDXX: 8.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IDXX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 2.6  Med: 15.10 Max: 92.6
Current: 8.7
2.6
92.6
EPS Growth (3Y)(%) 8.80
IDXX's EPS Growth (3Y)(%) is ranked higher than
61% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. IDXX: 8.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IDXX' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: 15.70 Max: 26.8
Current: 8.8
0
26.8
» IDXX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

IDXX Guru Trades in Q3 2014

Ray Dalio 7,113 sh (New)
Joel Greenblatt 155,323 sh (New)
Paul Tudor Jones 10,541 sh (+558.81%)
Jeremy Grantham 50,406 sh (+96.90%)
Jim Simons 292,052 sh (+92.90%)
Chris Davis 323,495 sh (+74.62%)
RS Investment Management 192,520 sh (+14.59%)
Bill Frels 3,199 sh (+6.67%)
Ron Baron 3,670,909 sh (-0.60%)
Ruane Cunniff 5,197,081 sh (-0.79%)
Chuck Royce 1,147,031 sh (-4.72%)
» More
Q4 2014

IDXX Guru Trades in Q4 2014

John Hussman 36,300 sh (New)
Jim Simons 318,752 sh (+9.14%)
Chris Davis 351,787 sh (+8.75%)
RS Investment Management 201,600 sh (+4.72%)
Ruane Cunniff 4,448,407 sh (unchged)
Ruane Cunniff 4,639,121 sh (unchged)
Ruane Cunniff 4,639,121 sh (unchged)
Ray Dalio Sold Out
Joel Greenblatt Sold Out
Ron Baron 3,623,004 sh (-1.30%)
Chuck Royce 994,811 sh (-13.27%)
Ruane Cunniff 4,448,407 sh (-14.41%)
Jeremy Grantham 41,800 sh (-17.07%)
Bill Frels 2,199 sh (-31.26%)
Paul Tudor Jones 2,200 sh (-79.13%)
» More
Q1 2015

IDXX Guru Trades in Q1 2015

Steven Cohen 2,000 sh (New)
Chris Davis 355,648 sh (+1.10%)
Bill Frels 2,199 sh (unchged)
Ron Baron 3,623,004 sh (unchged)
Paul Tudor Jones Sold Out
Ron Baron 3,614,135 sh (-0.24%)
Chuck Royce 957,011 sh (-3.80%)
Ruane Cunniff 4,078,152 sh (-8.32%)
Jim Simons 291,952 sh (-8.41%)
RS Investment Management 171,342 sh (-15.01%)
John Hussman 29,000 sh (-20.11%)
Jeremy Grantham 29,400 sh (-29.67%)
» More
Q2 2015

IDXX Guru Trades in Q2 2015

John Hussman Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with IDXX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on IDEXX Laboratories Inc

Baron Funds Comments on IDEXX Laboratories Inc - Mar 23, 2015

Shares of IDEXX Laboratories, Inc. (IDXX), a leader in veterinary diagnostics, rose in the fourth quarter on better-than-expected earnings and progress on moving to a direct distribution model in the U.S. IDEXX’s fundamentals continue to improve, with organic growth in its core business reaching 12% in the most recently reported quarter. We believe organic revenue growth at current levels is sustainable due to recent innovations in IDEXX’s portfolio of diagnostic products, instruments, data management tools, and geographic expansion. (Rebecca Ellin)

From Ron Baron (Trades, Portfolio)'s Baron Partners Fund Fourth Quarter 2014 Commentary.

Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories - May 02, 2014

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX), a leader in veterinary diagnostics, rose on evidence of improving organic growth and excitement around its launch of CatalystOne, a new diagnostic platform. During its most recent quarter, IDEXX's organic revenue growth improved from mid-single digits to 11%, helped by strong instrument sales and accelerating volumes for the associated consumables. We believe that recent innovations in its diagnostic products, data management capabilities, and its go-to-market strategy have positioned IDEXX to continue recent market share gains and to significantly accelerate its revenue growth.



From Baron Funds' first quarter 2014 commentary.





Check out Ron Baron latest stock trades

Top Ranked Articles about IDEXX Laboratories Inc

Baron Funds Comments on IDEXX Laboratories Inc
Shares of IDEXX Laboratories, Inc. (IDXX), a leader in veterinary diagnostics, rose in the fourth quarter on better-than-expected earnings and progress on moving to a direct distribution model in the U.S. IDEXX’s fundamentals continue to improve, with organic growth in its core business reaching 12% in the most recently reported quarter. We believe organic revenue growth at current levels is sustainable due to recent innovations in IDEXX’s portfolio of diagnostic products, instruments, data management tools, and geographic expansion. (Rebecca Ellin) Read more...
Ruane Cunniff Sells Portions of Five of its Top 10 Stakes
In contrast to its activity in the third quarter, when nearly half of its transactions involved buying stocks in companies that were new to its portfolio, the majority of Ruane Cunniff (Trades, Portfolio)’s fourth-quarter activity involved selling – including portions of five of its 10 largest existing stakes. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 57.10
IDXX's P/E(ttm) is ranked lower than
74% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.70 vs. IDXX: 57.10 )
Ranked among companies with meaningful P/E(ttm) only.
IDXX' s 10-Year P/E(ttm) Range
Min: 15.2  Med: 29.87 Max: 57.13
Current: 57.1
15.2
57.13
Forward P/E 32.68
IDXX's Forward P/E is ranked lower than
76% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.83 vs. IDXX: 32.68 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 56.80
IDXX's PE(NRI) is ranked lower than
73% of the 85 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.20 vs. IDXX: 56.80 )
Ranked among companies with meaningful PE(NRI) only.
IDXX' s 10-Year PE(NRI) Range
Min: 15.02  Med: 29.77 Max: 56.82
Current: 56.8
15.02
56.82
P/B 808.11
IDXX's P/B is ranked lower than
100% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.61 vs. IDXX: 808.11 )
Ranked among companies with meaningful P/B only.
IDXX' s 10-Year P/B Range
Min: 3.88  Med: 7.27 Max: 808.11
Current: 808.11
3.88
808.11
P/S 4.59
IDXX's P/S is ranked lower than
60% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.22 vs. IDXX: 4.59 )
Ranked among companies with meaningful P/S only.
IDXX' s 10-Year P/S Range
Min: 1.75  Med: 3.82 Max: 5.71
Current: 4.59
1.75
5.71
PFCF 67.97
IDXX's PFCF is ranked lower than
73% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.75 vs. IDXX: 67.97 )
Ranked among companies with meaningful PFCF only.
IDXX' s 10-Year PFCF Range
Min: 13.09  Med: 33.13 Max: 240
Current: 67.97
13.09
240
POCF 37.88
IDXX's POCF is ranked lower than
69% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.69 vs. IDXX: 37.88 )
Ranked among companies with meaningful POCF only.
IDXX' s 10-Year POCF Range
Min: 11.42  Med: 23.28 Max: 44.34
Current: 37.88
11.42
44.34
EV-to-EBIT 28.02
IDXX's EV-to-EBIT is ranked lower than
63% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.37 vs. IDXX: 28.02 )
Ranked among companies with meaningful EV-to-EBIT only.
IDXX' s 10-Year EV-to-EBIT Range
Min: 10.7  Med: 20.40 Max: 33.3
Current: 28.02
10.7
33.3
PEG 4.90
IDXX's PEG is ranked lower than
65% of the 37 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. IDXX: 4.90 )
Ranked among companies with meaningful PEG only.
IDXX' s 10-Year PEG Range
Min: 0.77  Med: 1.98 Max: 5.08
Current: 4.9
0.77
5.08
Shiller P/E 46.68
IDXX's Shiller P/E is ranked lower than
72% of the 53 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.42 vs. IDXX: 46.68 )
Ranked among companies with meaningful Shiller P/E only.
IDXX' s 10-Year Shiller P/E Range
Min: 20.58  Med: 40.09 Max: 56.06
Current: 46.68
20.58
56.06
Current Ratio 1.07
IDXX's Current Ratio is ranked lower than
90% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. IDXX: 1.07 )
Ranked among companies with meaningful Current Ratio only.
IDXX' s 10-Year Current Ratio Range
Min: 0.93  Med: 2.89 Max: 8.34
Current: 1.07
0.93
8.34
Quick Ratio 0.84
IDXX's Quick Ratio is ranked lower than
89% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. IDXX: 0.84 )
Ranked among companies with meaningful Quick Ratio only.
IDXX' s 10-Year Quick Ratio Range
Min: 0.73  Med: 2.03 Max: 7.55
Current: 0.84
0.73
7.55
Days Inventory 87.03
IDXX's Days Inventory is ranked lower than
54% of the 145 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.61 vs. IDXX: 87.03 )
Ranked among companies with meaningful Days Inventory only.
IDXX' s 10-Year Days Inventory Range
Min: 77.45  Med: 84.42 Max: 165.44
Current: 87.03
77.45
165.44
Days Sales Outstanding 47.54
IDXX's Days Sales Outstanding is ranked higher than
73% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.88 vs. IDXX: 47.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
IDXX' s 10-Year Days Sales Outstanding Range
Min: 37.43  Med: 42.10 Max: 91.54
Current: 47.54
37.43
91.54

Valuation & Return

vs
industry
vs
history
Price/DCF (Earnings Based) 2.09
IDXX's Price/DCF (Earnings Based) is ranked higher than
54% of the 13 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.09 vs. IDXX: 2.09 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Earnings Yield (Greenblatt) (%) 3.60
IDXX's Earnings Yield (Greenblatt) (%) is ranked higher than
68% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. IDXX: 3.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IDXX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 3  Med: 4.90 Max: 9.4
Current: 3.6
3
9.4
Forward Rate of Return (Yacktman) (%) 13.14
IDXX's Forward Rate of Return (Yacktman) (%) is ranked higher than
58% of the 53 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.08 vs. IDXX: 13.14 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
IDXX' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 13.1  Med: 17.30 Max: 22.1
Current: 13.14
13.1
22.1

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:IX1.Germany,
IDEXX Laboratories Inc was incorporated in 1983. The Company develops, manufactures and distributes products and provides services for the veterinary, bioresearch, water, livestock, poultry and dairy markets. It also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. The Company operates through three segments: CAG, Water, and LPD. CAG develops, designs, manufactures and distributes products and performs services for veterinarians and the bioresearch market related to diagnostics and information management. Water develops, designs, manufactures and distributes a products used in the detection of various microbiological parameters in water. LPD develops, designs, manufactures and distributes diagnostic tests and related instrumentation that are used to manage the health status of livestock and poultry, to improve bovine reproductive efficiency, and to ensure the quality and safety of milk and food. OPTI Medical develops, designs, manufactures and distributes point-of-care electrolyte and blood gas analyzers and related consumable products for the human medical diagnostics market. It competes with many companies ranging from large human pharmaceutical and medical diagnostics companies to small businesses focused on animal health. Its companion animal veterinary diagnostic products and services compete with both reference laboratory service and in-clinic product providers. The Company's trademarks include 4Dx, Catalyst Dx, Catalyst One, Coag Dx, Colilert, Colisure, Cornerstone, DVMAX, Enterolert, Feline Triple, Filta-Max, Filta-Max xpress, IDEXX I-Vision CR, IDEXX I-Vision DR, IDEXX I-Vision Mobile, IDEXX ImageBank, IDEXX-PACS, IDEXX VetLab, IDEXX VPM, LaserCyte, LaserCyte Dx, Navigator, OPTI, OPTI LION, PetChek, PetDetect, Pet Health Network, Practice Profile, ProCyte Dx, Pseudalert, Quanti-Tray, SimPlate, SmartService, SNAP, SNAPduo, SNAP Pro, SNAP cPL, SNAP fPL, SNAPshot Dx, VetAutoread, VetConnect, VetLab UA, VetLINK, VetLyte, VetStat, VetTest and VetVault. Many of its products are subject to comprehensive regulation by U.S. and foreign regulatory agencies that relate to, among other things, product approvals, manufacturing, distribution, marketing and promotion, labeling, recordkeeping, testing, quality, storage and product disposal.
» More Articles for IDXX

Headlines

Articles On GuruFocus.com
Baron Funds Spring Newsletter: The Advantages of Mid-Cap Stocks Jun 10 2015 
Distribution: A Potentially Under-appreciated Moat Jun 08 2015 
Baron Funds Comments on IDEXX Laboratories Inc Mar 23 2015 
Ron Baron's Baron Partners Fund Fourth Quarter 2014 Commentary Mar 20 2015 
Baron Asset Fund Commentary on IDEX Corp Mar 19 2015 
Ruane Cunniff Sells Portions of Five of its Top 10 Stakes Mar 13 2015 
Baron Funds Comments on IDEXX Laboratories May 02 2014 
IDEXX Laboratories, Inc. - Value Alert May 23 2013 
Weekly Top Insider Sells Feb 11 2013 
Weekly CFO Sells Highlight: FB, FSL, IVZ, IDXX, PFMT, CTXS Feb 10 2013 

More From Other Websites
10-Q for IDEXX Laboratories, Inc. Aug 01 2015
IDEXX Laboratories to Host 2015 Analyst Day Jul 31 2015
Edited Transcript of IDXX earnings conference call or presentation 30-Jul-15 12:30pm GMT Jul 30 2015
Idexx tops 2Q profit forecasts Jul 30 2015
Idexx tops 2Q profit forecasts Jul 30 2015
IDEXX LABORATORIES INC /DE Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 30 2015
IDEXX Laboratories Announces Second Quarter Results Jul 30 2015
5 Health Care Stocks to Trade for Gains -- Must-See Charts Jul 28 2015
Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 Jul 27 2015
IDEXX Laboratories (IDXX) in Focus: Stock Moves 10% Higher - Tale of the Tape Jul 23 2015
IDEXX Total T4 Thyroid Test Available on Catalyst Dx® and Catalyst One™ Chemistry Analyzers in... Jul 23 2015
IDEXX Total T4 Thyroid Test Available on Catalyst Dx and Catalyst One Chemistry Analyzers in North... Jul 23 2015
IDEXX Laboratories Introduces Innovative Point-of-Care Antibody Test for Canine Leptospirosis called... Jul 21 2015
IDEXX Laboratories Introduces Innovative Point-of-Care Antibody Test for Canine Leptospirosis Called... Jul 21 2015
IDEXX Elects Bruce L. Claflin to Board of Directors Jul 14 2015
IDEXX LABORATORIES INC /DE Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jul 14 2015
IDEXX Laboratories Elects Bruce L. Claflin to Board of Directors Jul 14 2015
IDEXX to Release 2015 Second Quarter Financial Results Jul 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK